Iias

Edit

Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

Lincoln Times-News 25 Dec 2025

SHANGHAI, Dec.

Edit

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for ...

The Galveston Daily News 18 Dec 2025

HANGZHOU, China--(BUSINESS WIRE)--Dec 18, 2025-- ....

Edit

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus

Pharmiweb 18 Dec 2025

The phase I/IIa clinical trial, QT-019B-001CN, is an open-label, single-arm, multicenter clinical study conducted in patients with rSLE.

Edit

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial ...

Nasdaq Globe Newswire 16 Dec 2025

... I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).

Edit

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 (Form 6-K) (Clearmind Medicine Inc)

Public Technologies 16 Dec 2025

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 ... The multinational Phase I/IIa trial is designed to assess the ...

Edit

IPA Director General participates in IIAS board meeting

Bahrain News Agency 10 Dec 2025

... of Directors of the International Institute of Administrative Sciences (IIAS), participated in the IIAS Board of Directors meeting.

Edit

First Patient Dosed in Part 2 of Modus Therapeutics’ Phase IIa Study in Chronic Kidney Disease with Anemia

Pharmiweb 10 Dec 2025

... has been dosed in Part 2 of the company’s ongoing Phase IIa clinical study evaluating sevuparin for the treatment of Chronic Kidney Disease (CKD) with anemia ... The Phase IIa study comprises two parts.

Edit

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

Nasdaq Globe Newswire 08 Dec 2025

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL ... .

Edit

IiAS raises concerns over oversight, culture at IndiGo

The Times of India 08 Dec 2025

A proxy advisory firm has raised concerns about InterGlobe Aviation's board ... .

Edit

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

Caledonian Record 04 Dec 2025

BERLIN--(BUSINESS WIRE)--Dec 4, 2025-- ....

Edit

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome (Bayer AG)

Public Technologies 04 Dec 2025

The Alport Syndrome Sema3A Efficacy & Safety Study (ASSESS) is a Phase IIa clinical trial with an investigational drug (BAY 3401016) for patients with Alport Syndrome.

Edit

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa ...

Nasdaq Globe Newswire 02 Dec 2025

... announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD).

Edit

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder (Form 6-K) (Clearmind Medicine Inc)

Public Technologies 02 Dec 2025

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder.

Edit

Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911

PR Newswire 01 Dec 2025

The completed Phase IIa clinical study (9MW1911-C03) was a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation trial ... The Phase IIa trial application has recently been accepted by the U.S.

Edit

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial ...

Nasdaq Globe Newswire 24 Nov 2025

... FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary, non-hallucinogenic neuroplastogen, in the treatment of Alcohol Use Disorder (AUD).

Podcasts:

Latest News for: iias

Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for ...

Qihan Biotech Initiates Dosing in Phase I/IIa Clinical Trial with Off-the-Shelf Allogeneic CAR-T Therapy for Refractory Systemic Lupus Erythematosus

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial ...

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 (Form 6-K) (Clearmind Medicine Inc)

IPA Director General participates in IIAS board meeting

First Patient Dosed in Part 2 of Modus Therapeutics’ Phase IIa Study in Chronic Kidney Disease with Anemia

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL

IiAS raises concerns over oversight, culture at IndiGo

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome (Bayer AG)

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa ...

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder (Form 6-K) (Clearmind Medicine Inc)

Annualized Severe COPD Exacerbation Rate Reduced by Over 40%: Mabwell Announces Phase IIa Results for Innovative Anti-ST2 Antibody 9MW1911

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial ...

Article Search

EXPLORE WN.com